Optimer Pharmaceuticals, Inc. (OPTR) Income Statement

Click line-items for a historical chart and %

Licensing
Research grants
Total revenues	20.07M
Cost of licensing
Research and development	10.94M
Marketing
General and administrative
Total operating expenses	47.19M
Income (loss) from operations	-27.12M
Interest income and other, net	249.12K
Consolidated net income (loss)	-26.87M
Net loss attributable to noncontrolling interest	0
Net income (loss) attributable to Optimer Pharmaceuticals, Inc.
Net income (loss) per share - basic (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)
Weighted average number of shares used to compute net income (loss) per share - basic (in shares)
Weighted average number of shares used to compute net income (loss) per share - diluted (in shares)

Entities mentioned with OPTR

View All Entities